An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Spotlight Therapeutics has appointed Antoine Yver, M.D., M.Sc., to its Board of Directors, enhancing its leadership with over 30 years of experience in drug development. Dr. Yver is recognized for his influential role in bringing significant cancer treatments like Enhertu, Tagrisso, and Lynparza to market. This strategic move aligns with Spotlight's mission to advance its TAGE platform for gene editing therapies aimed at various diseases. The company's growth trajectory is expected to benefit from Dr. Yver's expertise in oncology and immunology.
Positive
Appointment of Dr. Antoine Yver with 30+ years of experience in drug development.
Dr. Yver's track record includes successful drugs like Enhertu and Tagrisso.
Strategic leadership expected to advance Spotlight's TAGE platform.
Potential to enhance development of gene editing therapies.
Negative
None.
Dr. Yver Brings More Than 30 Years of Industry Experience Including 11 Different Biologics and Small Molecule New Drug Approvals
SAN FRANCISCO--(BUSINESS WIRE)--
Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE (Targeted Active Gene Editors) platform and advance lead therapeutic candidates towards the clinic.
“We are thrilled to welcome Antoine to Spotlight’s Board of Directors,” said Mary Haak-Frendscho, Ph.D., President and Chief Executive Officer of Spotlight. “Few people in our industry enjoy such a remarkable track record of successful drug development, exercising extreme rigor in following the science to deliver practice-changing medicines that serve patients with significant unmet medical needs.”
As Executive Vice President and Global Head of Oncology R&D at Daiichi Sankyo, Dr. Yver played a key role in the development of the new breakthrough cancer biologic, Enhertu®, that is redefining breast cancer treatment and promises to set a new standard of care, as well as other Daiichi Sankyo DXd ADCs. From 2009 to 2016, Dr. Yver held executive leadership positions at AstraZeneca, including SVP & Global Head of Oncology Development. Under his leadership, Tagrisso® and Lynparza® were successfully developed and commercialized for patients. Prior to joining AstraZeneca, Dr. Yver held roles at Merck, Johnson & Johnson, Aventis and Rhone-Poulenc Rorer. Dr. Yver is Executive Vice President and Chairman of Development at Centessa Pharmaceuticals plc and currently serves as an Independent Director of the Board of Directors at Sanofi.
“I am delighted to join the Spotlight Board and support the mission to unlock the full potential of gene editing and enable effective single administration therapeutics for patients,” said Dr. Yver. “Spotlight’s biologics-based delivery approach has the potential to forge a new generation of cell-targeted in vivo CRISPR gene editing medicines across multiple therapeutic areas.”
“Antoine’s deep insights and vast global pharma experience will help propel Spotlight to becoming a clinical stage company,” said Craig Gordon, M.D., Spotlight board member, Founder, CEO, and CIO of GordonMD™ Global Investments. “We look forward to working together to impact the strategic decisions of the company that will ultimately provide benefit to patients.”
About Spotlight Therapeutics
Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.
What are the qualifications of Antoine Yver, M.D., M.Sc. newly appointed to Spotlight Therapeutics' Board?
Antoine Yver has over 30 years of experience in the biotech industry, with expertise in oncology and immunology, and has played crucial roles in developing several successful cancer therapies.
What impact is Dr. Yver's appointment expected to have on Spotlight Therapeutics?
Dr. Yver's extensive experience is expected to strengthen Spotlight's strategic decisions and accelerate the development of its gene editing therapies.
What is Spotlight Therapeutics' TAGE platform?
The TAGE platform stands for Targeted Active Gene Editors and aims to deliver CRISPR gene editing therapies in vivo, targeting various diseases.
What has been Dr. Yver's contribution to the field of oncology?
Dr. Yver has contributed significantly to drug development, including the commercialization of Enhertu and Tagrisso, which are key treatments in oncology.
Centessa Pharmaceuticals plc American Depositary Shares
